SparingVision has raised €75m ($75.9m) in a series B financing round with the aim of driving two internal programs into the clinic as its gene-editing partnership with Intellia Therapeutics, Inc. makes preclinical strides.
Jeito Capital and UPMC Enterprises co-led the financing, with other participants including Ysios Capital, 4BIO Capital, Bpifranc and the venture...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?